Decision made following review of rising COVID-19 cases

Both PARP inhibitors receive positive opinions from CHMP

Swiss pharma company to acquire biotech for $449m (€380m)

Data presented at 2020 ESMO virtual congress

Viral vector manufacturer Vibalogics adds CEO to lead expansion, COVID-19 response kblankenship Mon, 09/21/2020 – 19:14

Updated Date: Mon, 14 Sep 2020 00:00:00 EDT

Updated Date: Mon, 14 Sep 2020 00:00:00 EDT

Holst and colleagues discuss the asthma risk to children of being exposed to fine particular matter (PM2.5).1 Their […]

FiercePharmaPolitics—White House, pharma pricing talks fell apart over demand for ‘Trump Cards’: NYT esagonowsky Mon, 09/21/2020 – 09:51

Chinese customs raids J&J CAR-T partner Legend’s office, puts new CEO under ‘residential surveillance’ aliu Mon, 09/21/2020 – […]